Novo's 'Flashy' Ozempic, Wegovy Price Cuts Unlikely To Impact LLY Stock, Says BofA

Eli Lilly reported that a combination of ixekizumab (Taltz) and tirzepatide (Zepbound) showed broader changes in psoriasis, immune, and metabolic biomarkers than ixekizumab alone in a phase 3b trial. The study, presented at a dermatology conference, suggests a link between psoriasis and obesity. Lilly noted that 61% of US psoriasis patients also have obesity or overweight with comorbidities. The combination therapy showed superior skin clearance and weight reduction in prior results.

Roche, Novartis, Pfizer, and Eli Lilly received FDA approvals for their drugs. Lupin and Lipocine also gained regulatory nods. Caribou Biosciences plans to cut workforce and discontinue programs. Several biopharma companies announced deals and partnerships. Stock prices for mentioned companies varied.

Eli Lilly's phase 3b TOGETHER-PsO trial showed its combination treatment of Taltz and Zepbound improved outcomes for patients with moderate-to-severe plaque psoriasis who are overweight or obese. The company's GF Value™ suggests it is modestly undervalued with a 25.4% margin of safety, and its GF Score™ is 98 out of 100, indicating strong financial health. Insiders have been net sellers, while 25 premium gurus hold LLY, with 12 adding and 10 trimming positions.

Eli Lilly presented data from the TOGETHER-PsO Phase 3b trial showing that combining Taltz (ixekizumab) and Zepbound (tirzepatide) led to broader biomarker responses in adults with psoriasis and obesity compared to Taltz alone. The trial, presented at the 2026 Fall Clinical Dermatology Conference, found greater reductions in inflammatory immune activity with the combination treatment.

Novo Nordisk (NVO) raised its 2026 outlook despite a share price drop due to pricing pressure concerns. Q2 2026 adjusted sales rose 7%, and operating profit increased 11%. The company aims for revenue growth in line with peers through 2030. Wegovy's weekly prescriptions topped 265,000, but Eli Lilly's drugs have overtaken Ozempic and Wegovy in the US market.

Eli Lilly (LLY) presented data from its Phase 3b TOGETHER-PsO trial, showing that combining Taltz (psoriasis treatment) with Zepbound (obesity therapy) led to broader biomarker changes than Taltz alone. The study suggests interconnected immune and metabolic pathways in patients with both psoriasis and obesity. LLY stock closed at $1,169.60, down 1.61%.